Le rituximab : une biothérapie originale dans les maladies auto-immunes - ScienceDirect
![Rituximab (TRUXIMA®) - Biosimilaire [Acthera]](https://acthera.univ-lille.fr/res/Dia_43_Rituximab_Final.png "Rituximab (TRUXIMA®) - Biosimilaire [Acthera]")
Rituximab (TRUXIMA®) - Biosimilaire [Acthera]
Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. | Semantic Scholar
Blog - Deciphering B Cell Cancers With a Rituximab Biosimilar
Mechanism of action of rituximab. Rituximab is a monoclonal antibody... | Download Scientific Diagram
Rituximab is a monoclonal antibody that recognises the transmembrane... | Download Scientific Diagram
Rituximab, an Anti‐CD20 Monoclonal Antibody: History and Mechanism of Action - Pescovitz - 2006 - American Journal of Transplantation - Wiley Online Library
Lymphocyte B antigène CD20 fragment peptidique épitope, lié au rituximab (fragment Fab). Indications pour l'administration de rituximab sont la leucémie et lymphome Photo Stock - Alamy
Lymphocyte B antigène CD20 fragment peptidique épitope, lié au rituximab (fragment Fab). Indications pour l'administration de rituximab sont la leucémie et lymphome Photo Stock - Alamy
Schematic illustration of the mechanism of action of rituximab. The... | Download Scientific Diagram
Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention | Oncogene
Clinical review: Serious adverse events associated with the use of rituximab - a critical care perspective | Critical Care | Full Text
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance | Oncogene
Frontiers | Implications of rituximab pharmacokinetic and pharmacodynamic alterations in various immune-mediated glomerulopathies and potential anti-CD20 therapy alternatives
Drug Insight: the mechanism of action of rituximab in autoimmune disease—the immune complex decoy hypothesis | Nature Reviews Rheumatology
Frontiers | Past, Present, and Future of Rituximab—The World's First Oncology Monoclonal Antibody Therapy
Frontiers | Past, Present, and Future of Rituximab—The World's First Oncology Monoclonal Antibody Therapy
What is RITUXAN® (rituximab) for GPA and MPA?
The proposed mechanisms of action for rituximab, a chimeric monoclonal... | Download Scientific Diagram
Clinical review: Serious adverse events associated with the use of rituximab - a critical care perspective | Critical Care | Full Text
Anticorps monoclonal anti-CD20 (rituximab) dans les maladies hématologiques et les affections auto-immunes Monoclonal anti-CD20
Randomized, Double-Blind, Pharmacokinetic Equivalence Trial Comparing DRL- Rituximab With MabThera in Patients With Diffuse Large B-Cell Lymphoma | JCO Global Oncology
Rituximab — Wikipédia
Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial - The Lancet Rheumatology
